2nd Glioblastoma Drug Development Summit

Memo

GBM Drug Development is the only devoted meeting for large pharma, biotech and pioneering academics which guarantees to unite all stakeholders under a mutual and ambitious objective of accelerating the practical discovery, translation, and clinical development of safe, effective and deliverable therapies to treat glioblastoma, an extremely aggressive cancer with a huge medical unmet need. Confronting specific and applied drug development obstacles with inadequate successful treatments, such as the knowledge of glioblastoma’s mechanisms of resistance and lack of penetration via the blood brain barrier, the 2nd GBM Drug Development Summit will help neuro-oncologists, neurosurgeons and oncology professionals from biopharma effectively translate their drug candidates into human clinical trials, whilst optimizing the clinical development process itself to evade further clinical failures. Brought direct to your home office with a jam-packed agenda and online virtual networking opportunities, this exclusive virtual summit will delve into the common challenges with developing GBM therapies, whilst striving to advance safe and effective therapeutic breakthroughs to patients in need. Prices:Conference Only - Drug Developer : USD 2099.0Conference Only - Academic/Not-For-Profit: USD 1799.0Conference Only - Service/Solution Provider: USD 2499.0 Speakers: Adilia Hormigo, Antonio Chiocca, Christophe Quéva, James Garner, Jann Sarkaria, Jeffrey Skolnik, Patrick Wen, Ranjit S. Bindra, William F. Elmquist, Brian Alexander, Colin Gerner, Dave Anderson, David Andrews, David Reardon, Jill Barnholtz-Sloan, Elizabeth Buck, Jim Connor, Jing Li, Linda Liau, Josh Allen, Josh Rubin, Justin Lathia, Meredith Moore, Michael Berens, Michael Lim, Petra Hamerlik, Rifaquat Rahman, Robert Dillman, Robert Fenstermaker, Susan Chang Time: 9:00 am - 5:00 pm